Novavax (NVAX) Activist Exit Reshapes The Story, Is It Still 61% Below Fair Value?

Novavax (NVAX) is back in focus after Shah Capital Fund LLC sold 2.87 million shares on 19 October 2026 and ended its activist efforts at the vaccine developer.

Recent trading has been choppy for Novavax, with the share price down 13.85% over the past week and 8.75% over the past month. The stock still shows a 90 day share price return of 29.51% and a 36.04% year to date gain, while the 1 year total shareholder return of 13.85% sits against a much weaker 5 year total shareholder return that declined 93.48%, suggesting momentum has picked up recently even though long term holders have experienced heavy losses.

Compare how the recent activist exit at Novavax stacks up against other potential movers by reviewing our hand picked 29 high quality undervalued stocks that could be setting up for their next phase.

Novavax is trying to turn a vaccine portfolio and big pharma partnerships into a durable business, while the share price reacts to an activist stepping back. Are you paying for genuine strength or just recent excitement?

Most Popular Narrative: 61% Undervalued

On the most followed narrative, Novavax is priced at $9.70 against a Fair Value of $25.00, pointing to a steep valuation gap that hinges on how far its royalty and milestone model can go.

Material transfer and licensing arrangements that give four of the top ten global pharmaceutical companies rights to more than 30 Matrix M exploration areas across infectious disease and oncology create a pipeline of potential follow on deals where any clinical progression can translate into incremental milestone and royalty revenue that current consensus may not attribute to specific line items yet.

See why 6 investors see Novavax as 61% undervalued.

Result: Fair Value of $25.00 (UNDERVALUED)

Still, the bullish Novavax narrative leans heavily on partner milestones arriving on schedule, while governance concerns and index removal could restrain the pace at which sentiment improves.

Find out about the key risks to this Novavax narrative.

Next Steps

Sentiment on Novavax is mixed, with sharp drawdowns in the rearview mirror and fresh optimism around partnerships starting to build again. Act quickly, review the data on both the upside and the downside, and weigh those 2 key rewards and 2 important warning signs

Looking for more Novavax investment ideas?

If Novavax has your attention, broaden your watchlist now and tap into fresh opportunities that could matter just as much to your long term returns.

• Target resilient cash generators by reviewing a list of solid balance sheet and fundamentals (24 results) that many investors overlook until strength is obvious in hindsight.
• Hunt for pricing gaps early with our curated 29 high quality undervalued stocks that might align better with your view on quality versus price.
• Prioritise stability and sleep better at night by checking a 30 resilient stocks with low risk scores before the crowd chases safety all at once.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com